{"prompt": "['11 July 2019', 'ARGX-113-1704', 'ARGX-113', 'Protocol Version 3.0, Final', 'Contract research', 'A person, or a group of persons (commercial, academic, or', 'organization (CRO):', 'other), who as an independent contractor with argenx BVBA,', 'assume(s) one or more obligations of argenx BVBA,', 'e.g., development of a protocol, selection and/or monitoring', 'of Investigators, evaluation of reports, preparation of', 'materials to be submitted to Health Authorities.', 'Database lock:', 'An action taken to prevent further changes to a trial database.', 'A database is locked after review, query resolution, data', 'cleaning and determination that it is ready for analysis.', 'Data Safety Monitoring', 'Independent group of experts that advises and whose', 'Board (DSMB):', 'responsibilities are to periodically review and evaluate the', 'accumulated trial data for participant safety, trial conduct and', 'progress and, when appropriate, efficacy and to make', 'recommendation to the Sponsor concerning the continuation,', 'modification or termination of the trial.', 'Eligible:', 'Qualified for randomization into the trial based upon strict', 'adherence to inclusion/exclusion criteria.', 'Good clinical practices', 'A standard for the design, conduct, performance, monitoring,', '(GCP):', 'auditing, recording, analyses, and reporting of clinical trials', 'that provides assurance that the data and reported results are', 'credible and accurate, and that the rights, integrity, and', 'confidentiality of trial subjects are protected. (International', 'Council for Harmonization [ICH] E6).', 'Institutional Review', 'An independent body (a review board or a committee,', 'Board (IRB)/Independent', 'institutional, regional, national, or supranational), constituted', 'Ethics Committee (IEC):', 'of medical professionals and non-medical members, whose', 'responsibility it is to ensure the protection of the rights,', 'safety and well-being of human subjects involved in a trial', 'and to provide public assurance of that protection, by, among', 'other things, reviewing and approving / providing favorable', 'opinion on, the trial protocol, the suitability of the', 'Investigator(s), facilities, and the methods and material to be', 'used in obtaining and documenting informed consent of the', 'trial subjects.', 'argenx BVBA', 'Confidential', 'Page 41 of 110']['11 July 2019', 'ARGX-113-1704', 'ARGX-113', 'Protocol Version 3.0, Final', 'Informed consent/', 'A process by which a clinical investigation participant', 'Informed consent form', 'voluntarily confirms his or her willingness to participate in a', '(ICF):', 'particular clinical trial, after having been informed of all', \"aspects of the trial that are relevant to the participant's\", 'decision to participate. Informed consent is documented by', 'means of a dated and signed informed consent form (ICF).', 'International Conference', 'The International Conference on Harmonization of Technical', 'on Harmonization (ICH):', 'Requirements for Registration of Pharmaceuticals for Human', 'Use (ICH) is a project that brings together the regulatory', 'authorities of Europe, Japan and the United States and', 'experts from the pharmaceutical industry in the three regions', 'to discuss scientific and technical aspects of pharmaceutical', 'product registration.', 'Investigational medicinal', 'A pharmaceutical form of an active ingredient or placebo', 'product:', 'being tested or used as a reference in a clinical trial,', 'including a product with a marketing authorization when', 'used in a way different from the approved form, or when', 'used for an unapproved indication, or when used to gain', 'further information about an approved use.', 'Protocol amendment:', 'A written description of a change(s) to or formal clarification', 'of a protocol.', 'Randomization:', 'Process of random attribution of treatment to subjects in', 'order to reduce bias of selection.', 'Treatment:', 'Term used throughout the clinical trial to denote a set of', 'investigational product(s) or marketed product(s) or placebo', 'intended to be administered to a subject, identified by a', 'unique number, according to the trial randomization or', 'treatment allocation.', 'argenx BVBA', 'Confidential', 'Page 42 of 110']\n\n###\n\n", "completion": "END"}